Niraj Mishra

Niraj Mishra

Auto-generated profile, based on publicly available information

Niraj Mishra

KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in npj Vaccines
Verified
Journal Article
Open access
PDF file
DKDieudonné B. Kum
Dieudonné B. Kum
NMNiraj Mishra
Niraj Mishra
RBRobbert Boudewijns
Robbert Boudewijns
IGIvan Gladwyn-Ng
Ivan Gladwyn-Ng
CAChristian Alfano
Christian Alfano
KDKai Dallmeier
Kai Dallmeier
The recent Zika virus (ZIKV) epidemic in the Americas led to an intense search for therapeutics and vaccines. Here we report the engineering of a chimeric virus vaccine candidate (YF-ZIKprM/E) by replacing the antigenic surface glycoproteins and the capsid anchor of YFV-17D with those of a prototypic Asian lineage ZIKV isolate. By intracellular passaging, a variant with adaptive mutations in the E protein was obtained. Unlike YFV-17D, YF-ZIKprM/E replicates poorly in mosquito cells. Also, YF-ZIKprM/E does not cause disease nor mortality in interferon α/β, and γ receptor KO AG129 mice nor following intracranial inoculation of BALB/c pups. A single dose as low as 1 × 102 PFU results, as early as 7 days post vaccination, in seroconversion to neutralizing antibodies and confers full protection in AG129 mice against stringent challenge with a lethal inoculum (105 LD50) of either homologous or heterologous ZIKV strains. Induction of multi-functional CD4+ and CD8+ T cell responses against ZIKV structural and YFV-17D non-structural proteins indicates that cellular immunity may also contribute to protection. Vaccine immunogenicity and protection was confirmed in other mouse strains, including after temporal blockade of interferon-receptors in wild-type mice to facilitate ZIKV replication. Vaccination of wild-type NMRI dams with YF-ZIKprM/E results in complete protection of foetuses against brain infections and malformations following a stringent intraplacental challenge with an epidemic ZIKV strain. The particular characteristic of YF-ZIKprM/E in terms of efficacy and its marked attenuation in mice warrants further exploration as a vaccine candidate.

28 April 2020 in mBio
Verified
Journal Article
Open access
PDF file
NMNiraj Mishra
Niraj Mishra
RBRobbert Boudewijns
Robbert Boudewijns
MSMichael Alexander Schmid
Michael Alexander Schmid
RMRafael Elias Marques
Rafael Elias Marques
SSSapna Sharma
Sapna Sharma
KDKai Dallmeier
Kai Dallmeier
Efficient and safe vaccines against yellow fever (e.g., YFV-17D) that provide long-lasting protection by rapidly inducing neutralizing antibody responses exist. However, the vaccine supply cannot cope with an increasing demand posed by urban outbreaks in recent years. Here we report that JE-CVax/Imojev, a YFV-17D-based chimeric Japanese encephalitis vaccine, also efficiently protects against YFV infection in mice. In case of shortage of the YFV vaccine during yellow fever outbreaks, (off-label) use of JE-CVax/Imojev may be considered. Moreover, wider use of JE-CVax/Imojev in Asia may lower the risk of the much-feared YFV spillover to the continent. More generally, chimeric vaccines that combine surface antigens and replication machineries of two distinct flaviviruses may be considered dual vaccines for the latter pathogen without induction of surface-specific antibodies. Following this rationale, novel flavivirus vaccines that do not hold a risk for antibody-dependent enhancement (ADE) of infection (inherent to current dengue vaccines and dengue vaccine candidates) could be designed.

30 August 2009 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
SSShailendra K. Saxena
Shailendra K. Saxena
NMNiraj Mishra
Niraj Mishra
RSRakhi Saxena
Rakhi Saxena
MSManeesh Singh
Maneesh Singh
AMAsha Mathur
Asha Mathur
Background: In the year 2005, an epidemic of Japanese encephalitis (JE) occurred in the northern states of India. The present study was planned to reconfirm the circulation of JE in the area and to assess the trend of the disease to slow down the burden of JE. Methodology: Surveillance was conducted to identify patients with acute encephalitis. Blood and cerebrospinal fluid specimens from suspected cases underwent pathological, serological, and demographic investigations. Viral testing for evidence of Japanese encephalitis virus (JEV) infection was also performed, either by IgM capture ELISA/RT-PCR or both. To identify circulating JEV strains, RT-PCR, sequencing and phylogenetic analysis was performed. Based on clinical cases reported between 1992 and 2008, the trend of JE infection in the state was analyzed to examine the dynamics of infection. Results: Our investigations (n = 38) revealed that only 55.3% cases were positive for JE. Pathological examination revealed marked pleocytosis in CSF (90±76.9 cells/mm3), and peripheral leucocytosis (64.7±8.86% neutrophils) with mild anemia. Males were more susceptible than females with a ratio of 1.63:1 and significant gender difference (P

1 January 2016 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
YDYannick Debing
Yannick Debing
NMNiraj Mishra
Niraj Mishra
EVErik Verbeken
Erik Verbeken
KRKaat Ramaekers
Kaat Ramaekers
KDKai Dallmeier
Kai Dallmeier
JNJohan Hendrik Neyts
Johan Hendrik Neyts
Hepatitis E virus (HEV) is one of the prime causes of acute viral hepatitis, whereas chronic hepatitis E is increasingly recognized as an important problem in the transplant setting. Nevertheless, the fundamental understanding of the biology of HEV replication is limited and there are few therapeutic options. The development of such therapies is partially hindered by the lack of a robust and convenient animal model. We propose the infection of athymic nude rats with the rat HEV strain LA-B350 as such a model. A cDNA clone pLA-B350 was constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in vivo. Furthermore, a subgenomic replicon pLA-B350/luc was constructed and validated for in vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral activity of alpha interferon, ribavirin and mycophenolic acid, than genotype 3 HEV. As a proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with comparable efficiency as the wild-type construct, confirming that LA-B350 is amenable to humanization. Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude rats, confirming the suitability of the rat model for antiviral studies.

1 January 2020 in Emerging Microbes & Infections
Verified
Journal Article
Open access
DKDieudonné Buh Kum
Dieudonné Buh Kum
RBRobbert Boudewijns
Robbert Boudewijns
JMJi Ma
Ji Ma
NMNiraj Mishra
Niraj Mishra
DSDomique Schols
Domique Schols
KDKai Dallmeier
Kai Dallmeier
The recent Zika virus (ZIKV) epidemic in the Americas, followed by the yellow fever virus (YFV) outbreaks in Angola and Brazil highlight the urgent need for safe and efficient vaccines against the ZIKV as well as much greater production capacity for the YFV-17D vaccine. Given that the ZIKV and the YFV are largely prevalent in the same geographical areas, vaccines that would provide dual protection against both pathogens may obviously offer a significant benefit. We have recently engineered a chimeric vaccine candidate (YF-ZIKprM/E) by swapping the sequences encoding the YFV-17D surface glycoproteins prM/E by the corresponding sequences of the ZIKV. A single vaccine dose of YF-ZIKprM/E conferred complete protection against a lethal challenge with wild-type ZIKV strains. Surprisingly, this vaccine candidate also efficiently protected against lethal YFV challenge in various mouse models. We demonstrate that CD8+ but not CD4+ T cells, nor ZIKV neutralizing antibodies are required to confer protection against YFV. The chimeric YF-ZIKprM/E vaccine may thus be considered as a dual vaccine candidate efficiently protecting mice against both the ZIKV and the YFV, and this following a single dose immunization. Our finding may be particularly important in the rational design of vaccination strategies against flaviviruses, in particular in areas where YFV and ZIKV co-circulate.

10 August 2006 in Eurosurveillance
Verified
Journal Article
Open access
SSS K Saxena
S K Saxena
MSM Singh
M Singh
NMN Mishra
N Mishra
VLV Lakshmi
V Lakshmi
Since December 2005, an outbreak of chikungunya virus (CHIKV) infection has been ongoing in various states of India